CD95 (Fas/APO-1) and its ligand (CD95L) belong to a growing cytokine a
nd cytokine receptor family that includes nerve growth factor (NGF) an
d tumor necrosis factor (TNF) and their corresponding receptors. CD95
expression increases during malignant progression from low-grade to an
aplastic astrocytoma and is most prominent in perinecrotic areas of gl
ioblastoma, There is, however, no evidence that CD95 expression in mal
ignant gliomas is triggered by hypoxia or ischemia. Agonistic antibodi
es to CD95, or the natural ligand, CD95L, induce apoptosis in human ma
lignant glioma cells in vitro, Glioma cell sensitivity to CD95-mediate
d apoptosis is regulated by CD95 expression at the cell surface and by
the revels of intracellular apoptosis-regulatory proteins, including
bcl-2 family members. Several cytotoxic drugs synergize with CD95L to
kill glioma cells, For as yet unknown reasons, glioma cells may coexpr
ess CD95 and CD95L in vitro without undergoing suicide or fratricide.
Yet, they kill T cells via CD95/CD95L interactions and are sensitive t
o exogenously added CD95L, Since CD95L is expressed in gliomas in vivo
, too, forced induction of CD95 expression might promote therapeutic a
poptosis in these tumors. That glioma cells differ from nontransformed
T cells in their sensitivity to CD95 antibodies or recombinant ligand
, may allow the development of selective CD95 agonists with high antit
umor activity that spare normal brain tissue, A family of death ligand
/receptor pairs related to CD95L/CD95, including APO2L (TRAIL) and its
multiple receptors is beginning to emerge. Although several issues re
garding glioma cell sensitivity to CD95L/CD95-mediated apoptosis await
elucidation, CD95 is a promising target for the treatment of malignan
t glioma.